<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749875</url>
  </required_header>
  <id_info>
    <org_study_id>APHP210093</org_study_id>
    <nct_id>NCT04749875</nct_id>
  </id_info>
  <brief_title>Study of Leukocyte Populations in Patients With Chronic Inflammatory</brief_title>
  <acronym>LIMA</acronym>
  <official_title>Study of Leukocyte Populations in Patients With Chronic Inflammatory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploration of pathophysiological mechanisms in chronic inflammatory rheumatism and rare&#xD;
      systemic autoimmune diseases with the objective of identifying therapeutic targets.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to characterization of the quantitative and qualitative&#xD;
      specificities of the different leukocyte sub-populations in patients with chronic&#xD;
      inflammatory rheumatism and rare systemic autoimmune diseases. We will perform an exploratory&#xD;
      descriptive study whom primary endpoint will be to assess by FACS the phenotype of the&#xD;
      specific leukocyte subsets. In addition, we will characterize the protein and transcriptomic&#xD;
      signature associated with the conditions for which we have obtained preliminary data showing&#xD;
      their potential involvement in autoimmunity (i.e: IL7 pathway, IFN signature).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization of the quantitative and qualitative specificities of the different leukocyte subpopulations in patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases</measure>
    <time_frame>At the end of the study (5 years)</time_frame>
    <description>Proportion of different leukocytes subset</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protein study (ELISA on serum) : IL7</measure>
    <time_frame>At the end of the study (5 years)</time_frame>
    <description>levels of IL7 and other cytokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptome study (RNA) : mRNA levels</measure>
    <time_frame>At the end of the study (5 years)</time_frame>
    <description>assessement of different mRRNA involved in Il7/IFN pathways by molecular biology techniques (RNAseq, qPCR, nano string)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genomic study (DNA) : SNPs</measure>
    <time_frame>At the end of the study (5 years)</time_frame>
    <description>Determination of the genotype of different SNPs involved in IL7/IFN pathways</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Systemic Autoimmune Disease</condition>
  <condition>Chronic Inflammatory Rheumatism</condition>
  <condition>Sjogren's Syndrome</condition>
  <condition>Spondyloarthritis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>sampling of blood for research during routine care</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum,&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Patient who did not express his opposition&#xD;
&#xD;
          -  Patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases&#xD;
             (pSS, lupus, scleroderma, myositis, unclassified connectivitis) diagnosed according to&#xD;
             the usual criteria.&#xD;
&#xD;
          -  Weight&gt; 35 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Corticosteroid treatment&gt; 10 mg / day&#xD;
&#xD;
          -  Pregnant patient&#xD;
&#xD;
          -  Patients under legal protection&#xD;
&#xD;
          -  Beneficiary of the state medical aid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaetane Nocturne</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xavier MARIETTE</last_name>
    <phone>00 33 1 45 21 37 58</phone>
    <email>xavier.mariette@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Xavier Mariette, MD, PhD</last_name>
      <phone>+33 (0)1 45 21 37 51</phone>
      <email>xavier.mariette@bct.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Gaetane Nocturne, MCU-PH</last_name>
      <phone>0033 1 45 21 37 57</phone>
      <email>gaetane.nocturne@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Xavier Mariette, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 6, 2021</study_first_submitted>
  <study_first_submitted_qc>February 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>February 6, 2021</last_update_submitted>
  <last_update_submitted_qc>February 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leukocytes</keyword>
  <keyword>macrophages</keyword>
  <keyword>lymphocytes</keyword>
  <keyword>rare systemic autoimmune diseases</keyword>
  <keyword>chronic inflammatory rheumatism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Fever</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

